IPSEN (OTCMKTS:IPSEY) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• IPSEN passed above its 200-day moving average — the 200-day MA is $40.00 and the stock traded as high as $48.0076 (last trade $48.0076) on light volume of 205 shares.
• Analyst sentiment is mixed: Deutsche Bank reaffirmed a "buy," UBS downgraded to "hold," and overall there is one Buy, one Hold and one Sell, giving an average rating of Hold.
• IPSEN is a global biopharmaceutical company focused on oncology, neuroscience and rare diseases, with key products including Cabometyx and Decapeptyl.

IPSEN (OTCMKTS:IPSEY - Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $40.00 and traded as high as $48.0076. IPSEN shares last traded at $48.0076, with a volume of 205 shares changing hands.

Analysts Set New Price Targets

IPSEY has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of IPSEN in a research report on Tuesday, April 14th. UBS Group lowered shares of IPSEN from a "strong-buy" rating to a "hold" rating in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, IPSEN has an average rating of "Hold".

IPSEN Stock Down 1.1%

The business's fifty day simple moving average is $46.44 and its two-hundred day simple moving average is $40.00.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company's oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.